1. Scrip
  2. >>New Products

Pfizer’s Hympavzi May Fall Into Hemophilia B Niche

 
• By Alaric DeArment

The US FDA approved the drug for hemophilia A and B, and while it may struggle to compete in hemophilia A against Roche’s Hemlibra, it has a big convenience advantage in hemophilia B.

• Source: Shutterstock

Pfizer Inc.’s Hympavzi (marstacimab-hncq) has a significant advantage over factor-replacement therapy in hemophilia A and hemophilia B, but it may struggle to compete against existing options in hemophilia A, meaning its greatest chance of commercial success will be leveraging the convenience advantage in hemophilia B. Still, it adds to the drug maker’s growing franchise in hemophilia, which includes a hemophilia B gene therapy that won approval earlier this year and a hemophilia A gene therapy likely on the way.

The FDA approved Hympavzi on 11 October as a prophylaxis to prevent or reduce the frequency of bleeding episodes in patients aged 12 and older with hemophilia A without factor VIII (FVIII) inhibitors and hemophilia B without factor IX inhibitors

Key Takeaways

  • The FDA approved Pfizer’s anti-TFPI monoclonal antibody, Hympavzi, for hemophilia A and hemophilia B.

  • Roche’s Hemlibra already dominates in the larger hemophilia A market, but Hympavzi has a significant convenience advantage in hemophilia B thanks to its subQ, flat-dose, weekly administration

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

More from Scrip

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.